VentriPoint Diagnostics Ltd (VPT) - Total Assets
Based on the latest financial reports, VentriPoint Diagnostics Ltd (VPT) holds total assets worth CA$377.12K CAD (≈ $272.80K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of VentriPoint Diagnostics Ltd to assess the company's total reinvestment commitment from operating cash flow.
VentriPoint Diagnostics Ltd - Total Assets Trend (2005–2024)
This chart illustrates how VentriPoint Diagnostics Ltd's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of VentriPoint Diagnostics Ltd to evaluate the quality of earnings relative to operating cash generation.
VentriPoint Diagnostics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
VentriPoint Diagnostics Ltd's total assets of CA$377.12K consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 9.2% |
| Accounts Receivable | CA$27.68K | 4.2% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how VentriPoint Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VentriPoint Diagnostics Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VentriPoint Diagnostics Ltd's current assets represent 72.1% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, down from 99.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 4.2% of total assets.
VentriPoint Diagnostics Ltd Competitors by Total Assets
Key competitors of VentriPoint Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Huvitz Co. Ltd
KQ:065510
|
Korea | ₩235.07 Billion |
|
Boule Diagnostics AB
ST:BOUL
|
Sweden | Skr465.40 Million |
|
Truscreen Group Ltd
AU:TRU
|
Australia | AU$4.30 Million |
|
NuGen Medical Devices Inc
V:NGMD
|
Canada | CA$10.19 Million |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
VentriPoint Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.28 | 0.39 |
| Quick Ratio | 0.05 | 0.28 | 0.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-4.65 Million | CA$-1.34 Million | CA$-1.11 Million |
VentriPoint Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between VentriPoint Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.13 |
| Latest Market Cap to Assets Ratio | 27.85 |
| Asset Growth Rate (YoY) | -65.1% |
| Total Assets | CA$658.02K |
| Market Capitalization | $18.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VentriPoint Diagnostics Ltd's assets at a significant premium (27.85x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: VentriPoint Diagnostics Ltd's assets decreased by 65.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VentriPoint Diagnostics Ltd (2005–2024)
The table below shows the annual total assets of VentriPoint Diagnostics Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$658.02K ≈ $476.00K |
-65.06% |
| 2023-12-31 | CA$1.88 Million ≈ $1.36 Million |
-68.49% |
| 2022-12-31 | CA$5.98 Million ≈ $4.32 Million |
-37.38% |
| 2021-12-31 | CA$9.54 Million ≈ $6.90 Million |
+1090.77% |
| 2020-12-31 | CA$801.57K ≈ $579.84K |
+155.05% |
| 2019-12-31 | CA$314.28K ≈ $227.35K |
-32.63% |
| 2018-12-31 | CA$466.49K ≈ $337.45K |
-72.72% |
| 2017-12-31 | CA$1.71 Million ≈ $1.24 Million |
+154.27% |
| 2016-12-31 | CA$672.50K ≈ $486.48K |
-69.15% |
| 2015-12-31 | CA$2.18 Million ≈ $1.58 Million |
+343.26% |
| 2014-12-31 | CA$491.74K ≈ $355.71K |
-35.36% |
| 2013-12-31 | CA$760.73K ≈ $550.30K |
-35.25% |
| 2012-12-31 | CA$1.17 Million ≈ $849.89K |
-51.91% |
| 2011-12-31 | CA$2.44 Million ≈ $1.77 Million |
+43.60% |
| 2010-12-31 | CA$1.70 Million ≈ $1.23 Million |
+727.09% |
| 2009-12-31 | CA$205.68K ≈ $148.79K |
-46.96% |
| 2008-12-31 | CA$387.79K ≈ $280.52K |
-87.50% |
| 2007-12-31 | CA$3.10 Million ≈ $2.24 Million |
+356.17% |
| 2006-12-31 | CA$679.97K ≈ $491.88K |
-3.01% |
| 2005-12-31 | CA$701.04K ≈ $507.13K |
-- |
About VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provid… Read more